NYSE:RDY Dr. Reddy's Laboratories (RDY) Stock Price, News & Analysis $14.19 +0.08 (+0.57%) Closing price 03:59 PM EasternExtended Trading$14.18 -0.01 (-0.11%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Dr. Reddy's Laboratories Stock (NYSE:RDY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get RDY alerts:Sign Up Key Stats Today's Range$14.15▼$14.3150-Day Range$11.54▼$14.1552-Week Range$11.36▼$15.67Volume1.79 million shsAverage Volume2.55 million shsMarket Capitalization$11.84 billionP/E Ratio38.35Dividend Yield0.42%Price Target$492.90Consensus RatingHold Company Overview Dr. Reddy’s Laboratories Limited is a global pharmaceutical company headquartered in Hyderabad, India. Founded in 1984 by Dr. Kallam Anji Reddy, the company develops, manufactures and markets medicines intended to make healthcare more accessible. Its business includes generic prescription drugs, active pharmaceutical ingredients, biosimilars, specialty products and over-the-counter consumer healthcare products. Dr. Reddy’s offers medicines across therapeutic areas such as cardiovascular care, diabetes, oncology, gastrointestinal health, pain management and dermatology. The company serves patients and healthcare providers in India, the United States, Europe and a range of other international markets, including emerging markets. Its operations span pharmaceutical research and development, manufacturing, regulatory services and commercial distribution. Dr. K. Satish Reddy serves as chairman, while G. V. Prasad is co-chairman and managing director and Erez Israeli is chief executive officer.AI Generated. May Contain Errors. Read More Dr. Reddy's Laboratories Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks87th Percentile Overall ScoreRDY MarketRank™: 4.356129032255 of 5 starsDr. Reddy's Laboratories scored higher than 87% of companies evaluated by MarketBeat, and ranked 51st out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingHold Consensus RatingDr. Reddy's Laboratories has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on no strong buy ratings, 2 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialDr. Reddy's Laboratories has a consensus price target of $492.90, representing about 3,382.2% upside from its current price of $14.16.Amount of Analyst CoverageDr. Reddy's Laboratories has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Dr. Reddy's Laboratories' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth28.89% Earnings GrowthEarnings for Dr. Reddy's Laboratories are expected to grow by 28.89% in the coming year, from $0.45 to $0.58 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dr. Reddy's Laboratories is 38.28, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.92.Price to Earnings Ratio vs. SectorThe P/E ratio of Dr. Reddy's Laboratories is 38.28, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 35.48.Price to Earnings Growth RatioDr. Reddy's Laboratories has a PEG Ratio of 2.95. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioDr. Reddy's Laboratories has a P/B Ratio of 2.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.20% of the float of Dr. Reddy's Laboratories has been sold short.Short Interest Ratio / Days to CoverDr. Reddy's Laboratories has a short interest ratio ("days to cover") of 8.45.Change versus previous monthShort interest in Dr. Reddy's Laboratories has recently decreased by 7.93%, indicating that investor sentiment is improving significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldDr. Reddy's Laboratories has a dividend yield of 0.45%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthDr. Reddy's Laboratories does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Dr. Reddy's Laboratories is 16.22%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Dr. Reddy's Laboratories will have a dividend payout ratio of 10.34% next year. This indicates that Dr. Reddy's Laboratories will be able to sustain or increase its dividend.Read more about Dr. Reddy's Laboratories' dividend. News and Social Media2.8 / 5News Sentiment0.49 News SentimentDr. Reddy's Laboratories has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Dr. Reddy's Laboratories this week, compared to 2 articles on an average week.Search Interest2 people have searched for RDY on MarketBeat in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Dr. Reddy's Laboratories insiders have not sold or bought any company stock.Percentage Held by Insiders2.00% of the stock of Dr. Reddy's Laboratories is held by insiders.Percentage Held by Institutions3.85% of the stock of Dr. Reddy's Laboratories is held by institutions.Read more about Dr. Reddy's Laboratories' insider trading history. Receive RDY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dr. Reddy's Laboratories and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RDY Stock News HeadlinesDr. Reddy's Laboratories Ltd (NYSE:RDY) Stock Has Average Price Target of $492.90 According to BrokeragesOctober 30 at 2:58 AM | americanbankingnews.comDr. Reddy's Laboratories (NYSE:RDY) Raised to "Neutral" at JPMorgan Chase & Co.October 28 at 2:29 AM | americanbankingnews.comYesterday's deadline changed everythingIn June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.October 30 at 1:00 AM | Behind the Markets (Ad)Dr. Reddy's Laboratories (NYSE:RDY) Shares Climb 4.8% on Earnings BeatOctober 28 at 1:52 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Dr Reddy’s Laboratories (RDY) and Genmab (GMAB)October 27 at 7:47 PM | theglobeandmail.comDr. Reddy's Laboratories: 3 Key Takeaways for Long-Term InvestorsOctober 25, 2026 | fool.comDr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call TranscriptOctober 23, 2026 | seekingalpha.comDr. Reddy’s outlines semaglutide relaunch in November 2026 and reiterates 6M-7M devices targetOctober 23, 2026 | seekingalpha.comSee More Headlines RDY Stock Analysis - Frequently Asked Questions How have RDY shares performed this year? Dr. Reddy's Laboratories' stock was trading at $14.03 on January 1st, 2026. Since then, RDY shares have increased by 0.9% and is now trading at $14.1550. How were Dr. Reddy's Laboratories' earnings last quarter? Dr. Reddy's Laboratories Ltd (NYSE:RDY) issued its earnings results on Saturday, October, 24th. The company reported $0.12 EPS for the quarter, beating analysts' consensus estimates of $0.10 by $0.02. The company earned $903.89 million during the quarter, compared to analysts' expectations of $894.94 million. Dr. Reddy's Laboratories had a trailing twelve-month return on equity of 7.91% and a net margin of 8.56%. Read the conference call transcript. When did Dr. Reddy's Laboratories' stock split? Dr. Reddy's Laboratories shares split before market open on Tuesday, November 5th 2024.The 5-1 split was announced on Thursday, September 12th 2024. The newly issued shares were distributed to shareholders after the closing bell on Monday, November 4th 2024. An investor that had 100 shares of stock prior to the split would have 500 shares after the split. Who are Dr. Reddy's Laboratories' major shareholders? Top institutional shareholders of Dr. Reddy's Laboratories include Robeco Institutional Asset Management B.V. (1.04%), Quadrant Capital Group LLC (0.02%), Frank Rimerman Advisors LLC (0.02%) and Greenleaf Trust (0.01%). How do I buy shares of Dr. Reddy's Laboratories? Shares of RDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dr. Reddy's Laboratories own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dr. Reddy's Laboratories investors own include Infosys (INFY), Johnson & Johnson (JNJ), Tata Motors (TTM), Walt Disney (DIS), ICICI Bank (IBN), Qualcomm (QCOM) and Wipro (WIT). Company Calendar Last Earnings10/24/2026Today10/30/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 4 days ago, RDY's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:RDY CIK1135951 Webwww.drreddys.com Phone914049002900Fax91-40-4900-2999Employees27,527Year Founded1984Price Target and Rating Average Price Target for Dr. Reddy's Laboratories$492.90 High Price Target$1,450.00 Low Price Target$13.90 Potential Upside/Downside+3,374.8%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$0.37 Trailing P/E Ratio38.34 Forward P/E Ratio31.52 P/E Growth2.95Net Income$456 million Net Margins8.56% Pretax Margin9.54% Return on Equity7.91% Return on Assets5.29% Debt Debt-to-Equity Ratio0.03 Current Ratio1.93 Quick Ratio1.39 Sales & Book Value Annual Sales$3.58 billion Price / Sales3.31 Cash Flow$0.85 per share Price / Cash Flow16.70 Book Value$4.87 per share Price / Book2.91Miscellaneous Outstanding Shares834,670,000Free Float817,978,000Market Cap$11.84 billion OptionableOptionable Beta0.29 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NYSE:RDY) was last updated on 10/30/2026 by MarketBeat.com Staff. From Our PartnersA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Withou...Behind the Markets | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredTwo charts tell you the future…Gold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dr. Reddy's Laboratories Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Dr. Reddy's Laboratories With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
